SYRS News and Press, Syros Pharmaceuticals Inc. From 02/08/23

Summary Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene overexpression, expected Q3 of 2024. The global myelodysplastic syndrome market is expected to reach $5.6 billion by 2032; 50% o...

The U.S. Food and Drug Administration (FDA) granted fast track designation to Syros Pharmaceuticals' ( NASDAQ: SYRS ) tamibarotene to treat higher-risk myelodysplastic syndrome (HR-MDS). MDS are a group of cancers in which immature blood cells in the bone marrow do not mature or becom...

-- Currently evaluating tamibarotene in combination with azacitidine pivotal SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed HR-MDS patients with RARA gene overexpression – Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new ...

Summary Syros Pharmaceuticals is developing cancer therapies. Its most advanced potential therapy is tamibarotene for MDS. The September merger with Tyme Technologies and cash raise provides a cash runway to 2025. Syros Pharmaceuticals ( SYRS ) is a small-cap, clinical sta...

-- Expect to Complete Enrollment in SELECT-MDS-1 Phase 3 Trial in 4Q 2023; Data Expected in 3Q 2024 -- -- On Track to Initiate Randomized Portion of SELECT-AML-1 Phase 2 Trial in 1Q 2023; Initial Data Expected 4Q 2023 -- -- Entering 2023 in Strong Financial Position, with Cash i...

Combination of tamibarotene and azacitidine in a Phase 2 trial demonstrated a high complete response rate, with rapid onset and clinically meaningful durability in newly diagnosed unfit acute myeloid leukemia (AML) patients with RARA overexpression Targeting RARA overexpression with tamib...

– 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression – - Initial safety and clinical activity profile of the triplet regimen supports advancing SELECT-AML-1 into the randomized portion– – Managem...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. Managem...

Syros Pharmaceuticals, Inc. (SYRS) Q3 2022 Earnings Conference Call November 14, 2022 08:30 AM ET Company Participants Karen Hunady - Director-Corporate Communications & Investor Relations Nancy Simonian - President & Chief Executive Officer David Roth - ...